Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Recruiting 2Withdrawn 1

Sponsor Class

OTHER 67INDUSTRY 26NETWORK 3FED 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3Adenocarcinoma 1

Interventions

Radiotherapy 299Cisplatin 263Cyclophosphamide 229Doxorubicin 176Paclitaxel 166Vincristine 160Carboplatin 149Filgrastim 139Etoposide 139Gemcitabine 118Fluorouracil 113Docetaxel 112Methotrexate 106Dexamethasone 106Cytarabine 106Prednisone 91Leucovorin 90Granulocyte Colony-Stimulating Factor 74Specimen Handling 65Magnetic Resonance Spectroscopy 61Capecitabine 59Irinotecan 58Radiation 54Ifosfamide 51Oxaliplatin 48Daunorubicin 48Temozolomide 47Radiotherapy, Conformal 47Platinum 47Peripheral Blood Stem Cell Transplantation 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NETWORK × Interventional × apalutamide × Clear all
NCT04423211 2026-05-15

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

Eastern Cooperative Oncology Group

Phase 3 Recruiting
804 enrolled
Genitourinary

Prostatic Neoplasms

NCT06592924 2026-04-14

TRIPLE-SWITCH

Canadian Cancer Trials Group

Phase 3 Recruiting
830 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT03488810 2020-08-17

ARN-509

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡